US slaps sanctions on Chinese, Mexican entities in fentanyl action
Adds Chinese embassy comment in paragraphs 10 and 11
By Daphne Psaledakis
WASHINGTON, May 30 (Reuters) -The United States on Tuesday imposed sanctions on 17 people and entities based in China and Mexico who it accused of enabling production of counterfeit fentanyl-laced pills, as the Biden administration seeks to stem imports of the deadly drug.
The Treasury Department said it slapped sanctions on seven entities and six people based in China, as well as one business and three people based in Mexico.
It accused those targeted of being involved in the sale of pill press machines and other equipment used to impress counterfeit trade markings like Xanax and M30 onto illicitly produced pills, often laced with fentanyl and destined for the United States.
"Treasury's sanctions target every stage of the deadly supply chain fueling the surge in fentanyl poisonings and deaths across the country," Treasury's Under Secretary for Terrorism and Financial Intelligence Brian Nelson said in a statement.
"Counterfeit pills laced with fentanyl constitute a leading cause of these deaths, devastating thousands of American families each year. We remain committed to using all authorities against enablers of illicit drug production to disrupt this deadly global production and counter the threat posed by these drugs."
The rate of drug overdose deaths involving the synthetic opioid fentanyl more than tripled in the United States from 2016 through 2021, according to a report by the U.S. Centers for Disease Control and Prevention (CDC) released this month.
Fentanyl is up to 50 times stronger than heroin and 100 times stronger than morphine, and has increasingly been mixed with other illicit drugs often with lethal results.
The Biden administration has been pushing for action as U.S. drug-related overdose deaths surpassed 100,000 in 2021, according to government estimates.
Washington has been seeking greater help from Beijing in stemming the illicit flow of fentanyl "precursor" chemicals from China, but U.S. officials have told Reuters that Chinese counterparts have been reluctant to cooperate as relations between the two countries have soured.
The spokesperson for China's Washington embassy, Liu Pengyu, condemned the Treasury move, saying Washington had "brazenly sanctioned Chinese individuals and entities" and this would "add more obstacles to China-US counter-narcotics cooperation."
Liu called it "a serious violation of the lawful rights and interests of the companies and individuals concerned" and said Washington was attempting to deflect blame instead of working to reduce the demand and strengthen management of prescription drugs.
Reporting by Daphne Psaledakis, Doina Chiacu and David Brunnstrom; Editing by Sharon Singleton and Jamie Freed
Pinakabagong Balita
Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.
Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.
Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.
